#USA #Intensity Therapeutics #Shelton #Triple Negative Breast Cancer #INVINCIBLE-4

Promising Developments in the Fight Against Triple-Negative Breast Cancer

Intensity Therapeutics, Inc. recently shared exciting preliminary findings from its ongoing INVINCIBLE-4 study, which is examining INT230-6 as a treatment option for patients with triple-negative breast cancer (TNBC). TNBC is known for being particularly aggressive, and the current standard of care (SOC) leaves much to be desired in terms of effectiveness and safety. The recent observations from the study showcase the potential of INT230-6 in improving patient outcomes while significantly reducing the risk of severe adverse events (AEs).

Study Overview

The INVINCIBLE-4 study is a Phase 2 non-comparative trial aiming to evaluate the efficacy, safety, and tolerability of INT230-6 when administered prior to standard immunochemotherapy treatments for early-stage, operable TNBC patients. As of now, 14 patients—seven in each of the two cohorts—have been treated, with the total expected enrollment reaching 61 patients. The primary endpoint of the study is the pathological complete response (pCR) rate, which refers to the absence of detectable cancer in breast tissue and lymph nodes following treatment.

Key Findings from INVINCIBLE-4

The preliminary data collected thus far indicate some noteworthy findings. Of the patients who received INT230-6 in combination with the SOC treatment (Cohort A), 71.4% achieved a pCR, while only 33% of those receiving the SOC alone (Cohort B) shared similar results. This stark contrast demonstrates the potential of INT230-6 to enhance treatment effectiveness.

Moreover, adverse event data is promising; Cohort A experienced 44% fewer grade 3 or higher AEs compared to Cohort B. This could significantly improve patient quality of life during treatment, a crucial aspect for those dealing with the physical and emotional toll of cancer therapies. The data highlighted a total of 14 serious AEs in Cohort A, with only one being a typical side effect related to immunotherapy. Conversely, Cohort B reported 25 AEs, four of which were severe or even fatal. This points to INT230-6 not only being effective in improving pCR rates but also in enhancing patient safety.

Context on TNBC Treatment

TNBC accounts for a notable portion of breast cancer cases, with approximately 56,000 new diagnoses each year in the U.S. alone. This subtype lacks certain hormone receptors, making it more challenging to treat effectively due to the limited number of targeted therapies available. As a result, most patients with localized TNBC opt for immunochemotherapy before surgery. The accepted treatment regimens have shown considerable toxicity, resulting in serious side effects for a significant portion of patients, as demonstrated in previous studies like Keynote-522, where 77% of patients suffered grade 3 or higher treatment-related AEs.

The compelling findings from the INVINCIBLE-4 study could change the treatment landscape for TNBC, offering hope for a less toxic and more effective therapeutic regimen.

Next Steps

Excitingly, Intensity Therapeutics has submitted a protocol amendment to the Swiss regulatory agency, Swissmedic, aimed at resuming enrollment with a refined treatment protocol that includes a lower drug volume per tumor ratio and employs a single injection of INT230-6. The changes intend to optimize safety and efficacy, ensuring that future patient cohorts can be treated under the best conditions possible.

As we await further detailed results, including updates from oncology conferences in the coming months, the initial findings provide a beacon of hope for the TNBC community. By reducing severe adverse events while concurrently improving treatment effectiveness, INT230-6 could mark a significant paradigm shift in managing this aggressive cancer subtype. Indeed, the future seems optimistic as researchers continue to explore innovative strategies to combat TNBC and improve patient outcomes.

In the words of Lewis H. Bender, the CEO of Intensity Therapeutics, the initial pCR data from this study is promising, especially regarding the observed safety profile. As more data emerges, the medical community remains hopeful for advancements in treatments that could dramatically shift the current paradigm for patients grappling with aggressive forms of breast cancer.